The 2019 San Antonio Breast Cancer Symposium (SABCS) was held from December 10 to 14 in San Antonio, Texas. In this podcast, Norah Lynn Henry, MD, PhD, FASCO, discusses 4 research highlights from the conference and what they mean for the treatment of breast cancer, including for people with HER2-positive metastatic breast cancer, triple-negative breast cancer, or hormone receptor-positive breast cancer.
Findings from the HER2CLIMB phase III clinical trial, which examined a new drug called tucatinib for the treatment of HER2-positive metastatic breast cancer. Tucatinib is a pill designed to turn off HER2. [2:10]
Findings from the DESTINY-Breast01 phase II clinical trial, which tested a new drug called trastuzumab deruxtecan (Enhertu), also for the treatment of HER2-positive metastatic breast cancer. This new drug includes trastuzumab (Herceptin), a standard targeted therapy, with a chemotherapy drug attached to it. [3:44]
Data from a meta-analysis of data from clinical trials using capecitabine (Xeloda) to treat stage I to stage III triple-negative breast cancer. Capecitabine is an oral chemotherapy that may be added to standard chemotherapy either at the same time of treatment or as an additional treatment following the completion of standard chemotherapy. This meta-analysis was done to see if adding capecitabine actually helps patients. [4:48]
Results of the NSABP B-42 clinical trial, which studied how long postmenopausal women with hormone receptor-positive breast cancer should be treated with the aromatase inhibitor letrozole (Femara). [7:25]
Dr. Henry is an associate professor in the University of Michigan's Division of Hematology/Oncology in the Department of Internal Medicine. She is the breast oncology disease lead at the Rogel Cancer Center. Dr. Henry specializes in the care of patients with all stages of breast cancer. She is the Cancer.Net Associate Editor for Breast Cancer.
Was this podcast useful? Please subscribe, rate, and review Cancer.Net Podcasts on Apple Podcasts or Google Play. This prerecorded podcast can be listened to online or downloaded to your computer. A transcript is also available. For more information, visit the Cancer.Net podcast page.